Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
September 10, 2018 (Issue: 1555)
The FDA has approved Roxybond (Daiichi Sankyo), an
short-acting (SA) oxycodone formulation with
abuse-deterrent properties, for treatment of pain
requiring management with an opioid. Roxybond
is the first SA opioid to be approved as an...more
- Opioids for pain. Med Lett Drugs Ther 2018; 60:57.
- Institute for Clinical and Economic Review. Abuse-deterrent formulations of opioids: effectiveness and value. New England Comparative Effectiveness Public Advisory Council, August 8, 2017. Available at: https://icer-review.org. Accessed August 30, 2018.
- Abuse-deterrent opioids. Med Lett Drugs Ther 2017; 59:95.
- LR Webster et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal human abuse potential study of oxycodone ARIR, a novel, immediate-release, abuse-deterrent formulation. Pain Med 2018 March 28 (epub).
- DH Solomon et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010; 170:1968.
- NT Vozoris et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2016; 48:683.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017; September 18 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed August 30, 2018.
- VE Whiteman et al. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy 2014; 2014:906723.
- Drugs for opioid use disorder. Med Lett Drugs Ther 2017; 59:89.
- A Shah et al. Characteristics of initial prescription episodes and likelihood of long-term opioid use – United States 2006-2015. MMWR Morb Mortal Wkly Rep 2017; 66:265.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
Article code: 1555a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
